Effects of a novel cholecystokinin (CCK) receptor antagonist, MK-329, on gallbladder contraction and gastric emptying in humans. Implications for the physiology of CCK.
Open Access
- 1 October 1989
- journal article
- research article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 84 (4) , 1220-1225
- https://doi.org/10.1172/jci114288
Abstract
To explore the physiology of cholecystokinin (CCK) in humans, we investigated the effect on gallbladder contraction and gastric emptying of a recently developed CCK receptor antagonist, MK-329. In a double-blind, four-period crossover study eight subjects received single doses of 0.5, 2, or 10 mg MK-329, or placebo, followed by an intravenous infusion of CCK-8 (30 pmol/kg.h). In placebo-treated subjects gallbladder volumes decreased on average to 43% of initial volumes after 2 h of CCK infusion. MK-329 caused a dose-dependent inhibition of CCK-stimulated gallbladder contraction with 10 mg producing complete blockade (P less than 0.01, cf. placebo). Gallbladder contraction and gastric emptying rates after a mixed meal were then measured in a two-period crossover study. Subjects received placebo or 10 mg of MK-329 2 h before eating. Gastric emptying of both solids and liquids was measured simultaneously by gamma scintigraphy. In placebo-treated subjects plasma CCK levels increased postprandially to 2.3 pM, gallbladder volumes decreased 68.4 +/- 3.8% (SE), and the times for 50% emptying of liquids and solids from the stomach were 58 +/- 10 and 128 +/- 8 min, respectively. In MK-329-treated subjects there was a marked elevation in peak CCK levels to 13.8 pM (P less than 0.01, cf. placebo), and gallbladder contraction was completely inhibited. Solid and liquid emptying rates were unaffected. These findings demonstrate that (a) MK-329 is a potent, orally active antagonist of CCK in humans, and (b) CCK is the major regulator of postprandial gallbladder contraction. These data also support the concept of negative feedback regulation of CCK secretion and suggest that mechanisms other than CCK play a dominant role in the regulation of postprandial gastric emptying rates.This publication has 24 references indexed in Scilit:
- Plasma cholecystokinin-octapeptide like immunoreactivity in patients with hepatic cirrhosisLife Sciences, 1987
- Jejunal bypass stimulation of pancreatic growth and cholecystokinin secretion in rats: importance of luminal nutrients.Gut, 1987
- A new simple mouse model for the in vivo evaluation of cholecystokinin (CCK) antagonists: Comparative potencies and durations of action of nonpeptide antagonistsLife Sciences, 1986
- Design of potent, orally effective, nonpeptidal antagonists of the peptide hormone cholecystokinin.Proceedings of the National Academy of Sciences, 1986
- Feedback regulation of pancreatic enzyme secretion. Suppression of cholecystokinin release by trypsin.Journal of Clinical Investigation, 1986
- Regulation of gastric emptying in humans by cholecystokinin.Journal of Clinical Investigation, 1986
- Cholecystokinin bioactivity in human plasma. Molecular forms, responses to feeding, and relationship to gallbladder contraction.Journal of Clinical Investigation, 1985
- Noncholecystokinin peptides in human serum which cause gallbladder contractionLife Sciences, 1982
- Production of rabbit antibody specific for amino-terminal residues of cholecystokinin octapeptide (CCK-8) by selective suppression of cross-reactive antibody responseJournal of Immunological Methods, 1982
- Feedback Regulation of Pancreatic Enzyme Secretion as a Mechanism for Trypsin Inhibitor-Induced Hypersecretion in RatsExperimental Biology and Medicine, 1972